Zolazepam
Basic information
- CAS
31352-82-6- Standard SMILES
Cc1nn(C)c2c1C(c1ccccc1F)=NCC(=O)N2C- InChIKey
GDSCFOSHSOWNDL-UHFFFAOYSA-N- Molecular formula
- C15H15FN4O
- Average molar mass
- 286.3 g/mol
- Monoisotopic mass
- 286.12298928
Overview
Zolazepam is a pyrazolodiazepinone derivative used as an anaesthetic in veterinary medicine. Zolazepam is typically used in combination with the NMDA antagonist tiletamine or the α2 adrenoceptor agonist xylazine. It is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.
Names & identifiers
- Preferred name
- Zolazepam
- IUPAC
- 4-(2-fluorophenyl)-1,3,8-trimethyl-6H-pyrazolo[5,4-e][1,4]diazepin-7-one
- English name
- Zolazepam
- Molecular formula
- C15H15FN4O
- Molecular weight
- 286.309
Names & synonyms
ZOLAZEPAM31352-82-6ZolazepamumCI 716G1R474U58UPyrazolo(3,4-e)(1,4)diazepin-7(1H)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-DTXSID30185278ZolasepamRefChem:196213DTXCID401077694-(2-fluorophenyl)-1,3,8-trimethyl-1H,6H,7H,8H-pyrazolo(3,4-e)(1,4)diazepin-7-oneFlupyrazapon
Show more names
CL-7164-(o-Fluorophenyl)-6,8-dihydro-1,3,8-triMethylpyrazolo[3,4-e][1,4]diazepin-7(1H)-one4-(2-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo[3,4-e][1,4]diazepin-7(1H)-one4-(2-Fluorophenyl)-6,8-dihydro-1,3,8-triMethylpyrazolo[3,4-e][1,4]diazepin-7(1H)-one-d3Pyrazolo[3,4-e][1,4]diazepin-7(1H)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-
Zolazepam [INN:BAN]Zolazepamum [INN-Latin]UNII-G1R474U58UDEA No. 72954-(2-fluorophenyl)-1,3,8-trimethyl-6H-pyrazolo[3,4-e][1,4]diazepin-7-one4-(2-Fluorophenyl)-1,3,8-trimethyl-6,8-dihydropyrazolo[3,4-e][1,4]diazepin-7(1H)-one4-(2-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)(1,4)diazepin-7(1H)-oneZOLAZEPAM [INN]
Properties
Computed structural properties
- XLogP
- 1.7
- Topological polar surface area
- 50.5 Ų
- Hydrogen bond donors
- 0
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 1
- Heavy atoms
- 21
- Formal charge
- 0
- Complexity
- 455
Experimental & physicochemical properties
Drugs
DEA NFLIS-Drug Category -> Benzodiazepines
Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds
Animal Drugs
Pharmaceuticals -> UK Veterinary Medicines Directorate List
Pharmaceuticals -> Animal Drugs -> Approved in Taiwan
Collision Cross Section162.3 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
Physicochemical properties
- Melting point
- 183 · 183-185 °C(Solv: methanol (67-56-1); ethyl ether (60-29-7))
- Boiling point
- 506.6 · 506.6±50.0 °C(Predicted)
- Density
- 1.31 · 1.31±0.1 g/cm3(Predicted)
- solubility
- 1 mg/ml; · DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml
- form
- A crystalline solid
- pka
- 1.85 · 1.85±0.20(Predicted)
- FDA UNII
- 1 R474U58U · G1R474U58U
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard information
Hazard Classes and CategoriesSkin Irrit. 2 (100%)
Safety data
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- Hazard statements
- H315-H335-H319
- Precautionary statements
- P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P
Chemistry & industry
Pharmacology
MeSH Pharmacological Classification
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.
Uses & manufacturing
Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Applications
UsesA sedative and anesthetic
Suppliers
Loading…
Open inquiries
Loading…
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…